Decibel Therapeutics (DBTX) announced the appointment of Matthew Kapusta to its Board of Directors. Matthew Kapusta has 25 years of experience in the life sciences industry and currently serves as Chief Executive Officer and Director of uniQure (QURE), a global gene therapy company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DBTX:
- Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Decibel downgraded to Market Perform from Outperform at SVB Securities
- Decibel Therapeutics reports Q4 cash position $104.6M vs $162.3M last year
- Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update